Trial
NCT03886493
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Regeneron Pharmaceuticals
Condition
Prostate Cancer
Intervention
Dupilumab
Why stopped
Low accrual due to COVID-19 pandemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15